At the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH), Professor Ying Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented a detailed summary of the latest research on CAR-T therapy for ALL. Her presentation covered the efficacy and safety of CAR-T therapies targeting various antigens, including CD19, CD22, and dual-target CAR-T approaches, as well as their application in specific patient populations. She also explored the factors influencing CAR-T therapy outcomes and discussed future directions to optimize this treatment for clinical use. Hematology Frontier has compiled the key insights from her presentation.

Published in Blood and presented at ASH 2024, the LUNA 3 study evaluates the efficacy and safety of rilzabrutinib, an oral Bruton Tyrosine Kinase Inhibitor (BTKi), in patients with previously…

Recently published in Blood, the DREPAGREFFE-2 trial provides crucial insights into long-term cognitive and cerebrovascular outcomes in children with sickle cell anemia (SCA) and a history of abnormal cerebral velocities.…

A recent study published in Blood (Volume 144, Supplement 1, November 5, 2024) explores the role of Lactate Dehydrogenase A (LDH-A) in CD8+ T cell differentiation and its impact on…

A study published in Blood on November 5, 2024, reveals how socioeconomic factors influence access to allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) patients. The findings indicate…